


PRODUCT INFORMATION



RGDV (trifluoroacetate salt)

Item No. 42965

Formal Name: L-arginylglycyl-L- α -aspartyl-L-valine, trifluoroacetate salt
Synonym: Arg-Gly-Asp-Val-OH
Peptide Sequence: RGDV-OH
MF: C₁₇H₃₁N₇O₇ • XCF₃COOH
FW: 445.5
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

RGDV (trifluoroacetate salt) is supplied as a solid. A stock solution may be made by dissolving the RGDV (trifluoroacetate salt) in the solvent of choice, which should be purged with an inert gas. RGDV (trifluoroacetate salt) is slightly soluble (0.1-1 mg/ml) in ethanol and DMSO.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of RGDV (trifluoroacetate salt) can be prepared by directly dissolving the solid in aqueous buffers. RGDV (trifluoroacetate salt) is sparingly soluble (1-10 mg/ml) in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

Description

RGDV is a tetrapeptide that contains an arginine-glycine-aspartate (RGD) motif, a sequence that acts as a recognition site for various adhesion proteins.¹ It inhibits the binding of fibrinogen to ADP-stimulated platelets and isolated human umbilical vein endothelial cells (HUVECs; IC₅₀s = 18 and 350 μ M, respectively).² RGDV, when conjugated to gemcitabine (Item Nos. 11690 | 9003096), decreases tumor weight and metastasis in an LLC1 murine lung cancer model.³

References

1. Park, H.S., Kim, C., and Kang, Y.K. Preferred conformations of RGD tetrapeptides to inhibit the binding of fibrinogen to platelets. *Biopolymers* **63**(5), 298-313 (2002).
2. Tranqui, L., Andrieux, A., Hudry-Clergeon, G., et al. Differential structural requirements for fibrinogen binding to platelets and to endothelial cells. *J. Cell Biol.* **108**(6), 2519-2527 (1989).
3. Zhang, X., Zhang, J., Liu, W., et al. Exploring the action of RGDV-gemcitabine on tumor metastasis, tumor growth and possible action pathway. *Sci. Rep.* **10**(1), 15729 (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/21/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM